Oryzon Genomics is a biopharmaceutical company focused on the research and development of innovative therapies based on epigenetics. The company primarily works in the fields of cancer and neurodegenerative diseases, leveraging its expertise in the modulation of gene expression to create novel drug candidates. Oryzon Genomics employs a strategic approach to drug discovery, utilizing proprietary technologies to develop compounds that can target specific biological pathways associated with disease. The company aims to provide new treatment options that can improve patient outcomes and address unmet medical needs.
Oryzon Genomics' stock surged by 21% to 3.69 euros, marking a 140% increase this year, with market capitalization exceeding 230 million euros. The rise is driven by positive Phase IIa…